Committee Approval Date:
Contributing or Reviewing Work Groups:
Structured Documents WG
FHIR Development Project Insight ID:
revision of project from a guidance document to FHIR IG is in progress
Scope of coverage:
This IG will address pharmacist- and pharmacy-specific requirements and terminologies relative to the C-CDA on FHIR IG, specifically the Consultation Note. This IG will also provide information on the C-CDA version of Pharmacist Consultant Note including mapping between the C-CDA and FHIR presentation. This IG builds upon an existing NCPDP Consultant Pharmacist Consult Note Guidance Document, specifically to add FHIR as an optional (or preferred) implementation. This is a joint NCPDP/HL7 project to publish under joint copyright.
Proposed IG Title:
Pharmacists Consultation Note IG
Proposed IG realm and code:
FHIR Core version(s):
R4, since C-CDA on FHIR IG STU 1.1 is based on R4
Joint maintenance between HL7 Pharmacy WG and NCPDP WG14 Long Term Post Acute Care (LTPAC) Clinical Pharmacist Interoperability Task Group.
This IG provides pharmacist- and pharmacy-specific guidance and requirements for the use of C-CDA on FHIR IG (STU 1.1) Consultation Note for a Pharmacist Consultation Note. This addresses sections that are required or recommended for a Pharmacist Consultation Note, which may differ from C-CDA on FHIR IG and US Core. Identifies required or recommended code sets/value sets for pharmacy use cases.
The Pharmacist Consultation Note IG provides requirements and recommendations for using C-CDA on FHIR IG (STU 1.1) Consultation Note in pharmacy use cases. The audience for this IG are system vendors, especially pharmacy system vendors, where the system/application supports pharmacists with medication review and other consulting services. Examples include: a pharmacist's medication regimen review for LTPAC patients; reporting of evaluations performed in a pharmacist-run clinic; and a pharmacist responding to a provider-requested review and recommendations for a patient's medications relative to their conditions, allergies, etc.
This IG also provides guidance on the use of C-CDA R2.1 for Pharmacist Consultation Notes. At the present time, C-CDA documents are widely used and previous guidance described C-CDA implementation for consulting pharmacists. This IG updates that prior guidance and includes material to facilitate the Pharmacist Consultation Note transition from C-CDA to FHIR (C-CDA on FHIR IG).
Pharmacy HIT Collaborative
National Community Pharmacists Association (NCPA) Innovation Center
American Society of Clinical Pharmacists (ASCP)
in discussion with
Requirements from subject matter experts in NCPDP, TabulaRasa, GeriMed, ASCP, PharmHIT
CMS-required Pharmacist Medication Regimen Review (MRR) for patients in Long Term and Post-Acute Care (LTPAC) facilities.
Provider-requested Pharmacist assessment of a patient's current medications. Common request in LTPAC and integrated medical systems.
dependent on C-CDA on FHIR IG 1.1.0 - (FHIR R4) STU Release 1.1 and its dependencies
no expected dependencies on this IG
Sept 2022 ballot